A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients

Aditi Kumar; Hafid O. Al-Hassi; Manushri Jain; Oliver Phipps; Clare Ford; Rousseau Gama; Helen Steed; Jeffrey Butterworth; John Mclaughlin; Niall Galbraith; Matthew J. Brookes; Lauren E. Hughes

doi:10.1038/s41598-022-12003-z

A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients

Aditi Kumar, Hafid O. Al-Hassi, Manushri Jain, Oliver Phipps, Clare Ford, Rousseau Gama, Helen Steed, Jeffrey Butterworth, John Mclaughlin, Niall Galbraith, Matthew J. Brookes, Lauren E. Hughes

Division of Diabetes, Endocrinology & Gastroenterology (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

This study examines the validity of measuring faecal bile acids (FBA) in a single stool sample as a diagnostic tool for bile acid diarrhoea (BAD) by direct comparison to the 75selenium-homotaurocholic acid (SeHCAT) scan. A prospective observational study was undertaken. Patients with chronic diarrhoea (> 6 weeks) being investigated for potential BAD with SeHCAT scan provided stool samples for measurement of FBA, using an enzyme-linked immunosorbent assay. Patients were characterised into four groups: SeHCAT negative control group, post-cholecystectomy, idiopathic BAD and post-operative terminal ileal resected Crohn’s disease. Stool samples were collected at baseline and 8-weeks post treatment to determine whether FBA measurement could be used to monitor therapeutic response. 113 patients had a stool sample to directly compare with their SeHCAT result. FBA concentrations (μmol/g) and interquartile ranges in patients in the control group (2.8; 1.6–4.2), BAD (3.6; 1.9–7.2) and post-cholecystectomy cohort 3.8 (2.3–6.8) were similar, but all were significantly lower (p 15% (2.6; 1.6–4.2); (p

Original language	English
Article number	8313
Journal	Scientific Reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41598-022-12003-z
Publication status	Published - 18 May 2022

Access to Document

10.1038/s41598-022-12003-zLicence: CC BY

https://www.nature.com/articles/s41598-022-12003-z

Cite this

Kumar, A., Al-Hassi, H. O., Jain, M., Phipps, O., Ford, C., Gama, R., Steed, H., Butterworth, J., Mclaughlin, J., Galbraith, N., Brookes, M. J., & Hughes, L. E. (2022). A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients. Scientific Reports, 12(1), Article 8313. https://doi.org/10.1038/s41598-022-12003-z

@article{0c87a0be94224f6f94b64a6f41d45b6c,

title = "A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients",

abstract = "This study examines the validity of measuring faecal bile acids (FBA) in a single stool sample as a diagnostic tool for bile acid diarrhoea (BAD) by direct comparison to the 75selenium-homotaurocholic acid (SeHCAT) scan. A prospective observational study was undertaken. Patients with chronic diarrhoea (> 6 weeks) being investigated for potential BAD with SeHCAT scan provided stool samples for measurement of FBA, using an enzyme-linked immunosorbent assay. Patients were characterised into four groups: SeHCAT negative control group, post-cholecystectomy, idiopathic BAD and post-operative terminal ileal resected Crohn{\textquoteright}s disease. Stool samples were collected at baseline and 8-weeks post treatment to determine whether FBA measurement could be used to monitor therapeutic response. 113 patients had a stool sample to directly compare with their SeHCAT result. FBA concentrations (μmol/g) and interquartile ranges in patients in the control group (2.8; 1.6–4.2), BAD (3.6; 1.9–7.2) and post-cholecystectomy cohort 3.8 (2.3–6.8) were similar, but all were significantly lower (p 15% (2.6; 1.6–4.2); (p ",

author = "Aditi Kumar and Al-Hassi, {Hafid O.} and Manushri Jain and Oliver Phipps and Clare Ford and Rousseau Gama and Helen Steed and Jeffrey Butterworth and John Mclaughlin and Niall Galbraith and Brookes, {Matthew J.} and Hughes, {Lauren E.}",

year = "2022",

month = may,

day = "18",

doi = "10.1038/s41598-022-12003-z",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

Kumar, A, Al-Hassi, HO, Jain, M, Phipps, O, Ford, C, Gama, R, Steed, H, Butterworth, J, Mclaughlin, J, Galbraith, N, Brookes, MJ & Hughes, LE 2022, 'A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients', Scientific Reports, vol. 12, no. 1, 8313. https://doi.org/10.1038/s41598-022-12003-z

TY - JOUR

T1 - A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients

AU - Kumar, Aditi

AU - Al-Hassi, Hafid O.

AU - Jain, Manushri

AU - Phipps, Oliver

AU - Ford, Clare

AU - Gama, Rousseau

AU - Steed, Helen

AU - Butterworth, Jeffrey

AU - Mclaughlin, John

AU - Galbraith, Niall

AU - Brookes, Matthew J.

AU - Hughes, Lauren E.

PY - 2022/5/18

Y1 - 2022/5/18

N2 - This study examines the validity of measuring faecal bile acids (FBA) in a single stool sample as a diagnostic tool for bile acid diarrhoea (BAD) by direct comparison to the 75selenium-homotaurocholic acid (SeHCAT) scan. A prospective observational study was undertaken. Patients with chronic diarrhoea (> 6 weeks) being investigated for potential BAD with SeHCAT scan provided stool samples for measurement of FBA, using an enzyme-linked immunosorbent assay. Patients were characterised into four groups: SeHCAT negative control group, post-cholecystectomy, idiopathic BAD and post-operative terminal ileal resected Crohn’s disease. Stool samples were collected at baseline and 8-weeks post treatment to determine whether FBA measurement could be used to monitor therapeutic response. 113 patients had a stool sample to directly compare with their SeHCAT result. FBA concentrations (μmol/g) and interquartile ranges in patients in the control group (2.8; 1.6–4.2), BAD (3.6; 1.9–7.2) and post-cholecystectomy cohort 3.8 (2.3–6.8) were similar, but all were significantly lower (p 15% (2.6; 1.6–4.2); (p

AB - This study examines the validity of measuring faecal bile acids (FBA) in a single stool sample as a diagnostic tool for bile acid diarrhoea (BAD) by direct comparison to the 75selenium-homotaurocholic acid (SeHCAT) scan. A prospective observational study was undertaken. Patients with chronic diarrhoea (> 6 weeks) being investigated for potential BAD with SeHCAT scan provided stool samples for measurement of FBA, using an enzyme-linked immunosorbent assay. Patients were characterised into four groups: SeHCAT negative control group, post-cholecystectomy, idiopathic BAD and post-operative terminal ileal resected Crohn’s disease. Stool samples were collected at baseline and 8-weeks post treatment to determine whether FBA measurement could be used to monitor therapeutic response. 113 patients had a stool sample to directly compare with their SeHCAT result. FBA concentrations (μmol/g) and interquartile ranges in patients in the control group (2.8; 1.6–4.2), BAD (3.6; 1.9–7.2) and post-cholecystectomy cohort 3.8 (2.3–6.8) were similar, but all were significantly lower (p 15% (2.6; 1.6–4.2); (p

U2 - 10.1038/s41598-022-12003-z

DO - 10.1038/s41598-022-12003-z

M3 - Article

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 8313

ER -

A single faecal bile acid stool test demonstrates potential efficacy in replacing SeHCAT testing for bile acid diarrhoea in selected patients

Abstract

Access to Document

Fingerprint

Cite this